SlideShare una empresa de Scribd logo
1 de 37
Inotropes and Vasopressors
Uppers, downers and squeezers
2
Aim of the session:
• Overview of inotropes and vasoactive
drugs
• Discuss case examples
• Hopefully feel more confident in their use.
3
Overview
Inotropes are indicated in acute conditions where there is low cardiac output (CO),
such as cardiogenic shock following myocardial infarction, acute decompensated
heart failure and low CO states after cardiac surgery
Different vasopressors work by a variety of means:
The adrenergic group of vasopressors work by stimulating the sympathetic nervous
system. Drugs in this group include noradrenaline, adrenaline and phenylephrine
which work by narrowing blood vessels and dopamine which stimulates the heart.
Vasopressin and terlipressin are called non-adrenergic vasopressors. They do not
act upon the heart or blood vessels, but increase blood pressure by reducing water
loss through urination.
The main mechanism of action for most inotropes involves increasing intracellular
calcium, either by increasing influx to the cell during the action potential or increasing
release from the sarcoplasmic reticulum
Inotropes
Inotropes influence the contractility of the heart…
• Positive inotropes – increase the force of contractility
• Negative inotrope – reduce contractility(some calcium channel
blockers)
Positive inotropes mimic the sympathetic nervous system that increasing
heart rate and contractility
Application to cardiogenic shock, acute heart failure, ventricular fibrillation
etc.
*drugs influencing the heart rate referred to as chronotropes
5
Its all about the OXYGEN!
For tissues to be oxygenated, 3 factors need to be considered:
1. Oxygen transfer across the alveolar-capillary membrane
2. Oxygen attachment to haemoglobin
3. Adequate cardiac output(CO) to move the oxyhaemoglobin compound to
the tissues.
This is what we are going to
be talking about
6
Two Limbs to Oxygenation
7
To increase CO we can…
1. Enhance circulating volume through fluid resuscitation (increasing preload)
2. Enhancing myocardial contractility with inotropes(their inotropic effect)
3. Manipulating heart rate with inotropes(their chronotropic effect)
REMEMBER:
Cardiac output(CO)=
Heart rate(HR) x Stroke Volume(SV)
8
Measuring cardiac output
• How do we commonly evaluate?
• How complex is this?
Tissue perfusion is dependent on mean arterial blood pressure (MAP), which is the product of CO and systemic
vascular resistance (SVR):*
MAP = CO × SVR
Reducing CO or SVR lowers the MAP and therefore reduces tissue perfusion.
CO is dependent on the stroke volume (SV) and heart rate (HR):
CO = HR × SV
……SIMPLE?
9
Remember this!
Stroke Volume is a complex aspect!
Affected by preload, afterload and
contractility
Preload (the degree to which ventricles are stretched before
contracting) correlates with the end diastolic volume (the volume of
blood in a ventricle at the end of filling).
It is important to optimise preload by correcting fluid balance before
starting inotropes, since there is little point in increasing the
contractility of the heart if its chambers are not filled optimally.
Central venous pressure (CVP) can be used as a surrogate
measure of preload.
10
So how does this stay balanced?
Parasympathetic nervous system down regulates
Sympathetic nervous system up regulates
11
A&P
12
Lets talk drugs
In the context of the SNS, drugs:
• Mimic or impair(stimulate or block)
• Directly(Agonist or antagonist)
• Indirectly- releasing endogenous Norad(metaraminol,, ephedrine at a1)
In the context of the PNS, drugs work on:
• Nicotinic and muscarinic receptors with Ach as neurotransmitter
• M2 muscarinic receptors- heart
Autonomic control of heart rate
Autonomic control of myocardial
contractility
Sympathetic Nervous System,
adrenaline and certain drugs have
positive inotropic effects- increase
contractility
Parasympathetic Nervous System,
and certain drugs have negative
inotropic effects- reduce contractility
Receptor type Location Action
a1
Peripheral, renal and coronary
circulation
Vasoconstriction
Increase in Systemic Vascular
resistance
Decrease Insulin release
A2 Peripheral circulation.
Vasoconstriction
Systemic Vascular resistance
ß1
Heart, Sinoatrial node and
myocardium
Increase in contractility and heart
rate
ß2
Lungs-bronchial smooth muscle;
peripheral and coronary
circulation-coronary arteries, AV
node
Vasodilation, bronchodilation
It’s all about the receptors…
So how do we treat this stuff?
18
Atropine-PNS
Anticholinergic drug- works as a competitive antagonist in
muscarinic receptors(M2= heart)
M2 muscarinic receptors are located in the heart, where they
act to slow the heart rate down to normal sinus rhythm after
negative stimulatory actions of the parasympathetic nervous
system, by slowing the speed of depolarization
Atropine therefore blocks and slows down signals to the heart,
increasing the heart rate
Adrenaline (Epinephrine)- SNS
A1,A2,B1,B2 Agonist
A non-selective b and a agonist
A sympathomimetic drug emulating the action of sympathetic nervous system.
Positive inotrope and chronotrope
Boosts cardiac function by increasing heart rate (chronotropy) and
contractility (ionotropy) – via β1 Agonist.
Vasoconstrictor at high dose… effecting alpha receptors
Vasodilator as low dose effecting β2 receptors resulting in bronchial smooth
muscle relaxant
Adrenaline 1mg/mL (1:1000) solution for injection.
Noradrenaline. (Norepinephrine)-SNS
Mainly an a1 Agonist
Because it acts mainly via a1 receptors in the heart, it is usually used as a
vasopressor (increasing Systemic Vascular Resistance(SVR) in order to maintain
Mean Arterial Pressure) rather than an actual inotrope.
Causes vasoconstriction(alpha-adrenergic action) and positive inotropic effect of the
heart and dilation of coronary arteries(beta-adrenergic action)
It is often used with other inotropes, such as dobutamine, to maintain adequate
perfusion.
Noradrenaline 1mg/mL concentrate for solution for infusion.
Dobutamine-SNS
Dobutamine is mainly a direct acting inotropic as a ß1 agonist and therefore increases
cardiac contractility and with mild chronotropic effects on the heart rate.
It also acts at ß2 receptors causing vasodilation and decreasing afterload. In order to ensure
adequate MAP.
Does not cause the release of noradrenaline and therefore to ensure adequate MAP
dobutamine should be used in combination with a vasopressor (eg, noradrenaline).
The main side effects are increased heart rate, arrhythmias and an increased myocardial
oxygen demand. (These can cause myocardial ischaemia.)
Used for heart failure for the above reasons
250mg vials
Vasopressin(ADH)
Increase reabsorption of water by the renal tubules
Cause contraction of smooth muscle of the gastrointestinal tract and
all parts of the vascular bed, especially the capillaries, small arterioles
and venules with less effect on the smooth musculature of the large
veins
20IU/ml
Metaraminol-SNS
Increases both systolic diastolic blood pressure
The pressor effect begins one to two minutes after intravenous
injection and lasts about 20 mins-1 hour
Positive inotropic effect on the heart and has a peripheral
vasoconstrictor action
Potent sympathomimetic-alpha agonist effects, mild beta 1 effects
Metaraminol 10mg/mL Solution for injection or infusion
Ephedrine-SNS
Stimulates both alpha and beta-adrenergic receptors indirectly and
also releases endogenous noradrenaline from its storage
site(substantia nigra)
Often used in operating theatres due to strong direct evidence
base for anaesthetic hypotension.
Phenylephrine-SNS
Also used mostly in operating theatres
Produces vasocontriction that lasts longer than adrenaline and ephedrine
Responses are more sustained tham those to adrenaline, lasting 20minutes after
IV inj. and as long as 50mins after SC inj.
Its action on the heart vs adrenaline/ephedrine, is that it slows the HR and
increases the stroke output, producing no disturbance to the rhythm
Powerful postsynaptic alpha-receptor stimulant with little effect on the beta-
receptors of the heart
Phenylephrine 10mg/mL Solution for injection or infusion
GTN-Direct Vasoactive
Glyceryl trinitrate produces a dose related dilation of both arterial and
venous beds
Decreases venous return to the heart, reducing left ventricular end
diastolic pressure and pulmonary capillary wedge pressure(preload)
Arteriolar relaxation reduces systemic vascular resistance and arterial
pressure(afterload)
Also dilates the coronary arteries, although this effect is short-lived.
Dopamine
This is a complicated inotrope because it’s effect is dose-dependent .
At lower doses,(0.5–2 microgram/kg/min) it exerts mainly dopaminergic
(Neurotransmitter…) effects and blood pressure does not change or decreases slightly.
Causes renal and mesenteric vasodilation-renal plasma flow, GFR and Na+ excretion
usually increase
At medium strength doses (2–10micrograms/kg/min) the ß1 inotropic effects are more
prominent and CO and Systolic BP increase. Total peripheral vasoconstriction is
relatively unchanged due to vasoconstriction (alpha effect) and muscle vasodilation(beta
effect)
At high doses (10–20micrograms/kg/min) a1 vasoconstriction is the main action. Systolic
and diastolic pressures increase
200 mg ampoules
Some less frequently
used drugs
Isoprenaline- has a similar profile to dobutamine
but tends to cause more tachycardia. It is sometimes
used for bradycardic patients/ complete heart block
requiring inotropic support.
Milrionone- positive inotropic and vasodilatory
activity, ventricular dysfunction by increasing SV and
LV contractility producing pulmonary vasodilation
Sodium Nitroprusside(SNP)-direct
vasoactive, relaxation of vascular smooth muscle
and dilation of peripheral arteries and veins, non-
selective compared to GTN
Levosimendan-decompensated heart
failure, increases calcium sensitivity of
myocytes by binding to cardiac troponin C,
smooth muscle relaxation
Terlipressin- similar profile to vasopressin,
vasoconstriction on the splanchinic blood
vessels and reduces blood flow to the portal
vein
Route of administration.
????
Peripheral administration is emerging (as it is in anaesthetic practice in the perioperative period) with a
recent systematic review of over 1300 patients suggesting the risk of doing so being lower than is
anecdotally cited.
D. H. Tian, C. Smyth, G. Keijzers, S. P. Macdonald, S. Peake, A. Udy and A. Delaney, “Safety of peripheral administration of
vasopressor medications: A systematic review,” Emergency Medicine Australasia, vol. 32, no. 2, pp. 220-227, 2020.
This review reported that extravasation events were uncommon (event rate 3.4%), with no reported
incidents of tissue necrosis or limb ischaemia.
The most common alternative to a PVC is the insertion of a central venous cannula (CVC) [2] [3].
Whilst the use of ultrasound-guided insertion will aid in the reduction of the incidence of such risks,
many remain clinically significant (such as pneumothorax, arterial injury, arrhythmias and catheter-
related infection) and so it seems sensible to consider circumstances wherein administration via PVC
may be preferable when there is a need for:
• stabilisation of critically unwell patients awaiting transfer to a critical care area;
• short term post-operative use;
• patient preference;
• or where central venous access would prove problematic.
The decision will ultimately come down to local policy and the responsible senior at the time.
Monitoring
Inotropes are usually only
used in clinical areas where
patients’ haemodynamics can
be monitored adequately.
Continuous monitoring of
MAP, CO and CVP allows
haemodynamic changes to be
detected and addressed
rapidly.
Summary
• Inotropic drugs are potentially dangerous so be very thorough
in checking
• Vascular access needs to be spot on
• On central lines always endeavour to use distal, brown
lumen(furthest)
• Wear gloves when preparing/assisting
• Know what the drug does and why we use it
• Don’t EVER make a mistake with inotropes or disconnect
them without direction
Case 1
Type 1 anaphylactic
reaction
Type 1 anaphylactic reaction
What will you need and
why?…
Case 2
Septic shock
How would you
approach this case ?
Please explain why ?
Case 3
Cardiac arrest (pre and post
resuscitation)
Case study 4
Cardiogenic shock
Dobutamine
Noradrenaline
Management of cardiogenic shock article
Inotropes and Vasopressors.pptx

Más contenido relacionado

La actualidad más candente

Tachy Arrhythmias - Approach to Management
Tachy Arrhythmias - Approach to ManagementTachy Arrhythmias - Approach to Management
Tachy Arrhythmias - Approach to ManagementArun Vasireddy
 
7. ACUTE LIVER FAILURE
7. ACUTE LIVER FAILURE7. ACUTE LIVER FAILURE
7. ACUTE LIVER FAILUREPratap Tiwari
 
Tolvaptan cme slide
Tolvaptan cme slideTolvaptan cme slide
Tolvaptan cme slideRaja Lahiri
 
Management of heart failure
Management of heart failureManagement of heart failure
Management of heart failureDr-Ajay Tripathi
 
Subarachnoid haemorrhage
Subarachnoid haemorrhageSubarachnoid haemorrhage
Subarachnoid haemorrhageSambit Dash
 
Cardiopulmonary interactions in pediatrics
Cardiopulmonary interactions in pediatricsCardiopulmonary interactions in pediatrics
Cardiopulmonary interactions in pediatricspune2013
 
Newer Oral Anticoagulant in Chronic Kidney Disease
Newer Oral Anticoagulant in Chronic Kidney DiseaseNewer Oral Anticoagulant in Chronic Kidney Disease
Newer Oral Anticoagulant in Chronic Kidney DiseaseAbdullah Ansari
 
atrial fibrillation- management
atrial fibrillation- management atrial fibrillation- management
atrial fibrillation- management amish117
 
Long presentation on mechanism of action of levosimendan 07.11.2014
Long presentation on mechanism of action of levosimendan 07.11.2014Long presentation on mechanism of action of levosimendan 07.11.2014
Long presentation on mechanism of action of levosimendan 07.11.2014Orion Pharma (Global Brand Manager)
 
Cardiorenal Syndrome (Clinical Implications and Treatment Strategies) - Dr. G...
Cardiorenal Syndrome (Clinical Implications and Treatment Strategies) - Dr. G...Cardiorenal Syndrome (Clinical Implications and Treatment Strategies) - Dr. G...
Cardiorenal Syndrome (Clinical Implications and Treatment Strategies) - Dr. G...NephroTube - Dr.Gawad
 
Novel Oral Anticoagulants (NOACs) in CKD & Dialysis Patients - How to Use? Wh...
Novel Oral Anticoagulants (NOACs) in CKD & Dialysis Patients - How to Use? Wh...Novel Oral Anticoagulants (NOACs) in CKD & Dialysis Patients - How to Use? Wh...
Novel Oral Anticoagulants (NOACs) in CKD & Dialysis Patients - How to Use? Wh...NephroTube - Dr.Gawad
 
Inotropic therapy for heart failure
Inotropic therapy for heart failureInotropic therapy for heart failure
Inotropic therapy for heart failureRaghu Kishore Galla
 
Intensive care nephrology
Intensive care nephrologyIntensive care nephrology
Intensive care nephrologyFarragBahbah
 
Inotropes & vasoactive agents
Inotropes & vasoactive agentsInotropes & vasoactive agents
Inotropes & vasoactive agentsManoj Prabhakar
 
Ionotropes and vasopressors
Ionotropes and vasopressorsIonotropes and vasopressors
Ionotropes and vasopressorsdrriyas03
 

La actualidad más candente (20)

Tachy Arrhythmias - Approach to Management
Tachy Arrhythmias - Approach to ManagementTachy Arrhythmias - Approach to Management
Tachy Arrhythmias - Approach to Management
 
7. ACUTE LIVER FAILURE
7. ACUTE LIVER FAILURE7. ACUTE LIVER FAILURE
7. ACUTE LIVER FAILURE
 
Tolvaptan cme slide
Tolvaptan cme slideTolvaptan cme slide
Tolvaptan cme slide
 
Renal Disease in HIV/AIDS
Renal Disease in HIV/AIDSRenal Disease in HIV/AIDS
Renal Disease in HIV/AIDS
 
Management of heart failure
Management of heart failureManagement of heart failure
Management of heart failure
 
Subarachnoid haemorrhage
Subarachnoid haemorrhageSubarachnoid haemorrhage
Subarachnoid haemorrhage
 
Cardiopulmonary interactions in pediatrics
Cardiopulmonary interactions in pediatricsCardiopulmonary interactions in pediatrics
Cardiopulmonary interactions in pediatrics
 
Newer Oral Anticoagulant in Chronic Kidney Disease
Newer Oral Anticoagulant in Chronic Kidney DiseaseNewer Oral Anticoagulant in Chronic Kidney Disease
Newer Oral Anticoagulant in Chronic Kidney Disease
 
Hyponatremia
HyponatremiaHyponatremia
Hyponatremia
 
atrial fibrillation- management
atrial fibrillation- management atrial fibrillation- management
atrial fibrillation- management
 
Long presentation on mechanism of action of levosimendan 07.11.2014
Long presentation on mechanism of action of levosimendan 07.11.2014Long presentation on mechanism of action of levosimendan 07.11.2014
Long presentation on mechanism of action of levosimendan 07.11.2014
 
Cardiorenal Syndrome (Clinical Implications and Treatment Strategies) - Dr. G...
Cardiorenal Syndrome (Clinical Implications and Treatment Strategies) - Dr. G...Cardiorenal Syndrome (Clinical Implications and Treatment Strategies) - Dr. G...
Cardiorenal Syndrome (Clinical Implications and Treatment Strategies) - Dr. G...
 
Vasopressors in icu
Vasopressors in icuVasopressors in icu
Vasopressors in icu
 
Chads2 vas score
Chads2 vas scoreChads2 vas score
Chads2 vas score
 
Novel Oral Anticoagulants (NOACs) in CKD & Dialysis Patients - How to Use? Wh...
Novel Oral Anticoagulants (NOACs) in CKD & Dialysis Patients - How to Use? Wh...Novel Oral Anticoagulants (NOACs) in CKD & Dialysis Patients - How to Use? Wh...
Novel Oral Anticoagulants (NOACs) in CKD & Dialysis Patients - How to Use? Wh...
 
Inotropic therapy for heart failure
Inotropic therapy for heart failureInotropic therapy for heart failure
Inotropic therapy for heart failure
 
Intensive care nephrology
Intensive care nephrologyIntensive care nephrology
Intensive care nephrology
 
Inotropes & vasoactive agents
Inotropes & vasoactive agentsInotropes & vasoactive agents
Inotropes & vasoactive agents
 
Ionotropes and vasopressors
Ionotropes and vasopressorsIonotropes and vasopressors
Ionotropes and vasopressors
 
Antiarrhythmic drugs satya
Antiarrhythmic drugs satya Antiarrhythmic drugs satya
Antiarrhythmic drugs satya
 

Similar a Inotropes and Vasopressors.pptx

Uppers downers and squeezers
Uppers downers and squeezersUppers downers and squeezers
Uppers downers and squeezersJesse Spurr
 
Inotropes especially noradrenaline PACU.pptx
Inotropes especially noradrenaline PACU.pptxInotropes especially noradrenaline PACU.pptx
Inotropes especially noradrenaline PACU.pptxAnaes6
 
1. Anti hypertensive drugs.pptx what's hypertension
1. Anti hypertensive drugs.pptx what's hypertension1. Anti hypertensive drugs.pptx what's hypertension
1. Anti hypertensive drugs.pptx what's hypertensionKhyber medical university
 
Myocardial Infarction treatment drugs
Myocardial Infarction treatment drugsMyocardial Infarction treatment drugs
Myocardial Infarction treatment drugsvarinder kumar
 
Starling Case Report
Starling Case ReportStarling Case Report
Starling Case Reporttheworxx
 
Effects of sympathomimetic drugs on the cardiovascular system
Effects of sympathomimetic drugs on the cardiovascular systemEffects of sympathomimetic drugs on the cardiovascular system
Effects of sympathomimetic drugs on the cardiovascular systemDomina Petric
 
Basic understandings in the Heart Failure
Basic understandings in the Heart FailureBasic understandings in the Heart Failure
Basic understandings in the Heart FailureAryendu kumar
 
Inotropes and their choice
Inotropes and their choiceInotropes and their choice
Inotropes and their choiceDharmraj Singh
 
Anti hyprtensive drugs pharmacology
Anti hyprtensive drugs pharmacologyAnti hyprtensive drugs pharmacology
Anti hyprtensive drugs pharmacologyDHINESHKUMAR V
 
THE USE OF INOTROPIC DRUGS IN CARDIAC SURGERY
THE USE OF INOTROPIC DRUGS IN CARDIAC SURGERYTHE USE OF INOTROPIC DRUGS IN CARDIAC SURGERY
THE USE OF INOTROPIC DRUGS IN CARDIAC SURGERYThierry Yunishe
 
Cardiovascular drugs-Antihypertensive drugs
Cardiovascular drugs-Antihypertensive drugsCardiovascular drugs-Antihypertensive drugs
Cardiovascular drugs-Antihypertensive drugsPavithra Pavi
 
bloodpressuremechanism-100423102316-phpapp01.pptx
bloodpressuremechanism-100423102316-phpapp01.pptxbloodpressuremechanism-100423102316-phpapp01.pptx
bloodpressuremechanism-100423102316-phpapp01.pptxNaziaUzma3
 

Similar a Inotropes and Vasopressors.pptx (20)

Uppers downers and squeezers
Uppers downers and squeezersUppers downers and squeezers
Uppers downers and squeezers
 
Heart failure 2
Heart failure 2Heart failure 2
Heart failure 2
 
Inotropes especially noradrenaline PACU.pptx
Inotropes especially noradrenaline PACU.pptxInotropes especially noradrenaline PACU.pptx
Inotropes especially noradrenaline PACU.pptx
 
1. Anti hypertensive drugs.pptx what's hypertension
1. Anti hypertensive drugs.pptx what's hypertension1. Anti hypertensive drugs.pptx what's hypertension
1. Anti hypertensive drugs.pptx what's hypertension
 
Myocardial Infarction treatment drugs
Myocardial Infarction treatment drugsMyocardial Infarction treatment drugs
Myocardial Infarction treatment drugs
 
Starling Case Report
Starling Case ReportStarling Case Report
Starling Case Report
 
Hypertension
HypertensionHypertension
Hypertension
 
Rat cardiovascular system
Rat cardiovascular systemRat cardiovascular system
Rat cardiovascular system
 
B p control mechanism
B p control mechanismB p control mechanism
B p control mechanism
 
Effects of sympathomimetic drugs on the cardiovascular system
Effects of sympathomimetic drugs on the cardiovascular systemEffects of sympathomimetic drugs on the cardiovascular system
Effects of sympathomimetic drugs on the cardiovascular system
 
Blood pressure
Blood pressureBlood pressure
Blood pressure
 
Vasoactive agents
Vasoactive agentsVasoactive agents
Vasoactive agents
 
Hypertension regulation
Hypertension   regulationHypertension   regulation
Hypertension regulation
 
Basic understandings in the Heart Failure
Basic understandings in the Heart FailureBasic understandings in the Heart Failure
Basic understandings in the Heart Failure
 
Inotropes and their choice
Inotropes and their choiceInotropes and their choice
Inotropes and their choice
 
Anti hyprtensive drugs pharmacology
Anti hyprtensive drugs pharmacologyAnti hyprtensive drugs pharmacology
Anti hyprtensive drugs pharmacology
 
THE USE OF INOTROPIC DRUGS IN CARDIAC SURGERY
THE USE OF INOTROPIC DRUGS IN CARDIAC SURGERYTHE USE OF INOTROPIC DRUGS IN CARDIAC SURGERY
THE USE OF INOTROPIC DRUGS IN CARDIAC SURGERY
 
Vasoactive and inotropic agents
Vasoactive and inotropic agentsVasoactive and inotropic agents
Vasoactive and inotropic agents
 
Cardiovascular drugs-Antihypertensive drugs
Cardiovascular drugs-Antihypertensive drugsCardiovascular drugs-Antihypertensive drugs
Cardiovascular drugs-Antihypertensive drugs
 
bloodpressuremechanism-100423102316-phpapp01.pptx
bloodpressuremechanism-100423102316-phpapp01.pptxbloodpressuremechanism-100423102316-phpapp01.pptx
bloodpressuremechanism-100423102316-phpapp01.pptx
 

Último

FAMILY in sociology for physiotherapists.pptx
FAMILY in sociology for physiotherapists.pptxFAMILY in sociology for physiotherapists.pptx
FAMILY in sociology for physiotherapists.pptxMumux Mirani
 
Advance Directives and Advance Care Planning: Ensuring Patient Voices Are Heard
Advance Directives and Advance Care Planning: Ensuring Patient Voices Are HeardAdvance Directives and Advance Care Planning: Ensuring Patient Voices Are Heard
Advance Directives and Advance Care Planning: Ensuring Patient Voices Are HeardVITASAuthor
 
Exploring the Integration of Homeopathy and Allopathy in Healthcare.pdf
Exploring the Integration of Homeopathy and Allopathy in Healthcare.pdfExploring the Integration of Homeopathy and Allopathy in Healthcare.pdf
Exploring the Integration of Homeopathy and Allopathy in Healthcare.pdfDharma Homoeopathy
 
Learn Tips for Managing Chemobrain or Mental Fogginess
Learn Tips for Managing Chemobrain or Mental FogginessLearn Tips for Managing Chemobrain or Mental Fogginess
Learn Tips for Managing Chemobrain or Mental Fogginessbkling
 
Field exchange, Issue 72 April 2024 FEX-72.pdf
Field exchange, Issue 72 April 2024 FEX-72.pdfField exchange, Issue 72 April 2024 FEX-72.pdf
Field exchange, Issue 72 April 2024 FEX-72.pdfMohamed Miyir
 
Preventing Common Nutritional Deficiencies In Poultry Flocks (PPT).pdf
Preventing Common Nutritional Deficiencies In Poultry Flocks (PPT).pdfPreventing Common Nutritional Deficiencies In Poultry Flocks (PPT).pdf
Preventing Common Nutritional Deficiencies In Poultry Flocks (PPT).pdfAditiAlishetty
 
lupus quiz.pptx for knowing lupus thoroughly
lupus quiz.pptx for knowing lupus thoroughlylupus quiz.pptx for knowing lupus thoroughly
lupus quiz.pptx for knowing lupus thoroughlyRitasman Baisya
 
arpita 1-1.pptx management of nursing service and education
arpita 1-1.pptx management of nursing service and educationarpita 1-1.pptx management of nursing service and education
arpita 1-1.pptx management of nursing service and educationNursing education
 
SARS Cov-2 INFECTION AND ITS EMERGING VARIANTS
SARS Cov-2 INFECTION AND ITS EMERGING VARIANTSSARS Cov-2 INFECTION AND ITS EMERGING VARIANTS
SARS Cov-2 INFECTION AND ITS EMERGING VARIANTSNehaSaini499770
 
The future of change - strategic translation
The future of change - strategic translationThe future of change - strategic translation
The future of change - strategic translationHelenBevan4
 
Biology class 12 assignment neet level practise chapter wise
Biology class 12 assignment neet level practise chapter wiseBiology class 12 assignment neet level practise chapter wise
Biology class 12 assignment neet level practise chapter wiseNAGKINGRAPELLY
 
2024 Compliatric Webinar Series - OSV Overview and Panel Discussion April 202...
2024 Compliatric Webinar Series - OSV Overview and Panel Discussion April 202...2024 Compliatric Webinar Series - OSV Overview and Panel Discussion April 202...
2024 Compliatric Webinar Series - OSV Overview and Panel Discussion April 202...Compliatric Where Compliance Happens
 
Back care and back massage. powerpoint presentation
Back care and back massage. powerpoint presentationBack care and back massage. powerpoint presentation
Back care and back massage. powerpoint presentationpratiksha ghimire
 
Incentive spirometry powerpoint presentation
Incentive spirometry powerpoint presentationIncentive spirometry powerpoint presentation
Incentive spirometry powerpoint presentationpratiksha ghimire
 
EMS Response to Terrorism involving Weapons of Mass Destruction
EMS Response to Terrorism involving Weapons of Mass DestructionEMS Response to Terrorism involving Weapons of Mass Destruction
EMS Response to Terrorism involving Weapons of Mass DestructionJannelPomida
 
Understanding Cholera: Epidemiology, Prevention, and Control.pdf
Understanding Cholera: Epidemiology, Prevention, and Control.pdfUnderstanding Cholera: Epidemiology, Prevention, and Control.pdf
Understanding Cholera: Epidemiology, Prevention, and Control.pdfSasikiranMarri
 
Enhancing Health Through Personalized Nutrition
Enhancing Health Through Personalized NutritionEnhancing Health Through Personalized Nutrition
Enhancing Health Through Personalized NutritionNeighborhood Trainer
 
Professional Ear Wax Cleaning Services for Your Home
Professional Ear Wax Cleaning Services for Your HomeProfessional Ear Wax Cleaning Services for Your Home
Professional Ear Wax Cleaning Services for Your HomeEarwax Doctor
 
ANTIGEN- SECTION IMMUNOLOGY DEPARTMENT OF MICROBIOLOGY
ANTIGEN- SECTION IMMUNOLOGY  DEPARTMENT OF MICROBIOLOGYANTIGEN- SECTION IMMUNOLOGY  DEPARTMENT OF MICROBIOLOGY
ANTIGEN- SECTION IMMUNOLOGY DEPARTMENT OF MICROBIOLOGYDrmayuribhise
 

Último (20)

Dr Sujit Chatterjee Hiranandani Hospital Kidney.pdf
Dr Sujit Chatterjee Hiranandani Hospital Kidney.pdfDr Sujit Chatterjee Hiranandani Hospital Kidney.pdf
Dr Sujit Chatterjee Hiranandani Hospital Kidney.pdf
 
FAMILY in sociology for physiotherapists.pptx
FAMILY in sociology for physiotherapists.pptxFAMILY in sociology for physiotherapists.pptx
FAMILY in sociology for physiotherapists.pptx
 
Advance Directives and Advance Care Planning: Ensuring Patient Voices Are Heard
Advance Directives and Advance Care Planning: Ensuring Patient Voices Are HeardAdvance Directives and Advance Care Planning: Ensuring Patient Voices Are Heard
Advance Directives and Advance Care Planning: Ensuring Patient Voices Are Heard
 
Exploring the Integration of Homeopathy and Allopathy in Healthcare.pdf
Exploring the Integration of Homeopathy and Allopathy in Healthcare.pdfExploring the Integration of Homeopathy and Allopathy in Healthcare.pdf
Exploring the Integration of Homeopathy and Allopathy in Healthcare.pdf
 
Learn Tips for Managing Chemobrain or Mental Fogginess
Learn Tips for Managing Chemobrain or Mental FogginessLearn Tips for Managing Chemobrain or Mental Fogginess
Learn Tips for Managing Chemobrain or Mental Fogginess
 
Field exchange, Issue 72 April 2024 FEX-72.pdf
Field exchange, Issue 72 April 2024 FEX-72.pdfField exchange, Issue 72 April 2024 FEX-72.pdf
Field exchange, Issue 72 April 2024 FEX-72.pdf
 
Preventing Common Nutritional Deficiencies In Poultry Flocks (PPT).pdf
Preventing Common Nutritional Deficiencies In Poultry Flocks (PPT).pdfPreventing Common Nutritional Deficiencies In Poultry Flocks (PPT).pdf
Preventing Common Nutritional Deficiencies In Poultry Flocks (PPT).pdf
 
lupus quiz.pptx for knowing lupus thoroughly
lupus quiz.pptx for knowing lupus thoroughlylupus quiz.pptx for knowing lupus thoroughly
lupus quiz.pptx for knowing lupus thoroughly
 
arpita 1-1.pptx management of nursing service and education
arpita 1-1.pptx management of nursing service and educationarpita 1-1.pptx management of nursing service and education
arpita 1-1.pptx management of nursing service and education
 
SARS Cov-2 INFECTION AND ITS EMERGING VARIANTS
SARS Cov-2 INFECTION AND ITS EMERGING VARIANTSSARS Cov-2 INFECTION AND ITS EMERGING VARIANTS
SARS Cov-2 INFECTION AND ITS EMERGING VARIANTS
 
The future of change - strategic translation
The future of change - strategic translationThe future of change - strategic translation
The future of change - strategic translation
 
Biology class 12 assignment neet level practise chapter wise
Biology class 12 assignment neet level practise chapter wiseBiology class 12 assignment neet level practise chapter wise
Biology class 12 assignment neet level practise chapter wise
 
2024 Compliatric Webinar Series - OSV Overview and Panel Discussion April 202...
2024 Compliatric Webinar Series - OSV Overview and Panel Discussion April 202...2024 Compliatric Webinar Series - OSV Overview and Panel Discussion April 202...
2024 Compliatric Webinar Series - OSV Overview and Panel Discussion April 202...
 
Back care and back massage. powerpoint presentation
Back care and back massage. powerpoint presentationBack care and back massage. powerpoint presentation
Back care and back massage. powerpoint presentation
 
Incentive spirometry powerpoint presentation
Incentive spirometry powerpoint presentationIncentive spirometry powerpoint presentation
Incentive spirometry powerpoint presentation
 
EMS Response to Terrorism involving Weapons of Mass Destruction
EMS Response to Terrorism involving Weapons of Mass DestructionEMS Response to Terrorism involving Weapons of Mass Destruction
EMS Response to Terrorism involving Weapons of Mass Destruction
 
Understanding Cholera: Epidemiology, Prevention, and Control.pdf
Understanding Cholera: Epidemiology, Prevention, and Control.pdfUnderstanding Cholera: Epidemiology, Prevention, and Control.pdf
Understanding Cholera: Epidemiology, Prevention, and Control.pdf
 
Enhancing Health Through Personalized Nutrition
Enhancing Health Through Personalized NutritionEnhancing Health Through Personalized Nutrition
Enhancing Health Through Personalized Nutrition
 
Professional Ear Wax Cleaning Services for Your Home
Professional Ear Wax Cleaning Services for Your HomeProfessional Ear Wax Cleaning Services for Your Home
Professional Ear Wax Cleaning Services for Your Home
 
ANTIGEN- SECTION IMMUNOLOGY DEPARTMENT OF MICROBIOLOGY
ANTIGEN- SECTION IMMUNOLOGY  DEPARTMENT OF MICROBIOLOGYANTIGEN- SECTION IMMUNOLOGY  DEPARTMENT OF MICROBIOLOGY
ANTIGEN- SECTION IMMUNOLOGY DEPARTMENT OF MICROBIOLOGY
 

Inotropes and Vasopressors.pptx

  • 1. Inotropes and Vasopressors Uppers, downers and squeezers
  • 2. 2 Aim of the session: • Overview of inotropes and vasoactive drugs • Discuss case examples • Hopefully feel more confident in their use.
  • 3. 3 Overview Inotropes are indicated in acute conditions where there is low cardiac output (CO), such as cardiogenic shock following myocardial infarction, acute decompensated heart failure and low CO states after cardiac surgery Different vasopressors work by a variety of means: The adrenergic group of vasopressors work by stimulating the sympathetic nervous system. Drugs in this group include noradrenaline, adrenaline and phenylephrine which work by narrowing blood vessels and dopamine which stimulates the heart. Vasopressin and terlipressin are called non-adrenergic vasopressors. They do not act upon the heart or blood vessels, but increase blood pressure by reducing water loss through urination. The main mechanism of action for most inotropes involves increasing intracellular calcium, either by increasing influx to the cell during the action potential or increasing release from the sarcoplasmic reticulum
  • 4. Inotropes Inotropes influence the contractility of the heart… • Positive inotropes – increase the force of contractility • Negative inotrope – reduce contractility(some calcium channel blockers) Positive inotropes mimic the sympathetic nervous system that increasing heart rate and contractility Application to cardiogenic shock, acute heart failure, ventricular fibrillation etc. *drugs influencing the heart rate referred to as chronotropes
  • 5. 5 Its all about the OXYGEN! For tissues to be oxygenated, 3 factors need to be considered: 1. Oxygen transfer across the alveolar-capillary membrane 2. Oxygen attachment to haemoglobin 3. Adequate cardiac output(CO) to move the oxyhaemoglobin compound to the tissues. This is what we are going to be talking about
  • 6. 6 Two Limbs to Oxygenation
  • 7. 7 To increase CO we can… 1. Enhance circulating volume through fluid resuscitation (increasing preload) 2. Enhancing myocardial contractility with inotropes(their inotropic effect) 3. Manipulating heart rate with inotropes(their chronotropic effect) REMEMBER: Cardiac output(CO)= Heart rate(HR) x Stroke Volume(SV)
  • 8. 8 Measuring cardiac output • How do we commonly evaluate? • How complex is this? Tissue perfusion is dependent on mean arterial blood pressure (MAP), which is the product of CO and systemic vascular resistance (SVR):* MAP = CO × SVR Reducing CO or SVR lowers the MAP and therefore reduces tissue perfusion. CO is dependent on the stroke volume (SV) and heart rate (HR): CO = HR × SV ……SIMPLE?
  • 9. 9 Remember this! Stroke Volume is a complex aspect! Affected by preload, afterload and contractility Preload (the degree to which ventricles are stretched before contracting) correlates with the end diastolic volume (the volume of blood in a ventricle at the end of filling). It is important to optimise preload by correcting fluid balance before starting inotropes, since there is little point in increasing the contractility of the heart if its chambers are not filled optimally. Central venous pressure (CVP) can be used as a surrogate measure of preload.
  • 10. 10 So how does this stay balanced? Parasympathetic nervous system down regulates Sympathetic nervous system up regulates
  • 12. 12 Lets talk drugs In the context of the SNS, drugs: • Mimic or impair(stimulate or block) • Directly(Agonist or antagonist) • Indirectly- releasing endogenous Norad(metaraminol,, ephedrine at a1) In the context of the PNS, drugs work on: • Nicotinic and muscarinic receptors with Ach as neurotransmitter • M2 muscarinic receptors- heart
  • 13. Autonomic control of heart rate
  • 14. Autonomic control of myocardial contractility Sympathetic Nervous System, adrenaline and certain drugs have positive inotropic effects- increase contractility Parasympathetic Nervous System, and certain drugs have negative inotropic effects- reduce contractility
  • 15. Receptor type Location Action a1 Peripheral, renal and coronary circulation Vasoconstriction Increase in Systemic Vascular resistance Decrease Insulin release A2 Peripheral circulation. Vasoconstriction Systemic Vascular resistance ß1 Heart, Sinoatrial node and myocardium Increase in contractility and heart rate ß2 Lungs-bronchial smooth muscle; peripheral and coronary circulation-coronary arteries, AV node Vasodilation, bronchodilation It’s all about the receptors…
  • 16. So how do we treat this stuff?
  • 17.
  • 18. 18 Atropine-PNS Anticholinergic drug- works as a competitive antagonist in muscarinic receptors(M2= heart) M2 muscarinic receptors are located in the heart, where they act to slow the heart rate down to normal sinus rhythm after negative stimulatory actions of the parasympathetic nervous system, by slowing the speed of depolarization Atropine therefore blocks and slows down signals to the heart, increasing the heart rate
  • 19. Adrenaline (Epinephrine)- SNS A1,A2,B1,B2 Agonist A non-selective b and a agonist A sympathomimetic drug emulating the action of sympathetic nervous system. Positive inotrope and chronotrope Boosts cardiac function by increasing heart rate (chronotropy) and contractility (ionotropy) – via β1 Agonist. Vasoconstrictor at high dose… effecting alpha receptors Vasodilator as low dose effecting β2 receptors resulting in bronchial smooth muscle relaxant Adrenaline 1mg/mL (1:1000) solution for injection.
  • 20. Noradrenaline. (Norepinephrine)-SNS Mainly an a1 Agonist Because it acts mainly via a1 receptors in the heart, it is usually used as a vasopressor (increasing Systemic Vascular Resistance(SVR) in order to maintain Mean Arterial Pressure) rather than an actual inotrope. Causes vasoconstriction(alpha-adrenergic action) and positive inotropic effect of the heart and dilation of coronary arteries(beta-adrenergic action) It is often used with other inotropes, such as dobutamine, to maintain adequate perfusion. Noradrenaline 1mg/mL concentrate for solution for infusion.
  • 21. Dobutamine-SNS Dobutamine is mainly a direct acting inotropic as a ß1 agonist and therefore increases cardiac contractility and with mild chronotropic effects on the heart rate. It also acts at ß2 receptors causing vasodilation and decreasing afterload. In order to ensure adequate MAP. Does not cause the release of noradrenaline and therefore to ensure adequate MAP dobutamine should be used in combination with a vasopressor (eg, noradrenaline). The main side effects are increased heart rate, arrhythmias and an increased myocardial oxygen demand. (These can cause myocardial ischaemia.) Used for heart failure for the above reasons 250mg vials
  • 22. Vasopressin(ADH) Increase reabsorption of water by the renal tubules Cause contraction of smooth muscle of the gastrointestinal tract and all parts of the vascular bed, especially the capillaries, small arterioles and venules with less effect on the smooth musculature of the large veins 20IU/ml
  • 23. Metaraminol-SNS Increases both systolic diastolic blood pressure The pressor effect begins one to two minutes after intravenous injection and lasts about 20 mins-1 hour Positive inotropic effect on the heart and has a peripheral vasoconstrictor action Potent sympathomimetic-alpha agonist effects, mild beta 1 effects Metaraminol 10mg/mL Solution for injection or infusion
  • 24. Ephedrine-SNS Stimulates both alpha and beta-adrenergic receptors indirectly and also releases endogenous noradrenaline from its storage site(substantia nigra) Often used in operating theatres due to strong direct evidence base for anaesthetic hypotension.
  • 25. Phenylephrine-SNS Also used mostly in operating theatres Produces vasocontriction that lasts longer than adrenaline and ephedrine Responses are more sustained tham those to adrenaline, lasting 20minutes after IV inj. and as long as 50mins after SC inj. Its action on the heart vs adrenaline/ephedrine, is that it slows the HR and increases the stroke output, producing no disturbance to the rhythm Powerful postsynaptic alpha-receptor stimulant with little effect on the beta- receptors of the heart Phenylephrine 10mg/mL Solution for injection or infusion
  • 26. GTN-Direct Vasoactive Glyceryl trinitrate produces a dose related dilation of both arterial and venous beds Decreases venous return to the heart, reducing left ventricular end diastolic pressure and pulmonary capillary wedge pressure(preload) Arteriolar relaxation reduces systemic vascular resistance and arterial pressure(afterload) Also dilates the coronary arteries, although this effect is short-lived.
  • 27. Dopamine This is a complicated inotrope because it’s effect is dose-dependent . At lower doses,(0.5–2 microgram/kg/min) it exerts mainly dopaminergic (Neurotransmitter…) effects and blood pressure does not change or decreases slightly. Causes renal and mesenteric vasodilation-renal plasma flow, GFR and Na+ excretion usually increase At medium strength doses (2–10micrograms/kg/min) the ß1 inotropic effects are more prominent and CO and Systolic BP increase. Total peripheral vasoconstriction is relatively unchanged due to vasoconstriction (alpha effect) and muscle vasodilation(beta effect) At high doses (10–20micrograms/kg/min) a1 vasoconstriction is the main action. Systolic and diastolic pressures increase 200 mg ampoules
  • 28. Some less frequently used drugs Isoprenaline- has a similar profile to dobutamine but tends to cause more tachycardia. It is sometimes used for bradycardic patients/ complete heart block requiring inotropic support. Milrionone- positive inotropic and vasodilatory activity, ventricular dysfunction by increasing SV and LV contractility producing pulmonary vasodilation Sodium Nitroprusside(SNP)-direct vasoactive, relaxation of vascular smooth muscle and dilation of peripheral arteries and veins, non- selective compared to GTN Levosimendan-decompensated heart failure, increases calcium sensitivity of myocytes by binding to cardiac troponin C, smooth muscle relaxation Terlipressin- similar profile to vasopressin, vasoconstriction on the splanchinic blood vessels and reduces blood flow to the portal vein
  • 30. Peripheral administration is emerging (as it is in anaesthetic practice in the perioperative period) with a recent systematic review of over 1300 patients suggesting the risk of doing so being lower than is anecdotally cited. D. H. Tian, C. Smyth, G. Keijzers, S. P. Macdonald, S. Peake, A. Udy and A. Delaney, “Safety of peripheral administration of vasopressor medications: A systematic review,” Emergency Medicine Australasia, vol. 32, no. 2, pp. 220-227, 2020. This review reported that extravasation events were uncommon (event rate 3.4%), with no reported incidents of tissue necrosis or limb ischaemia. The most common alternative to a PVC is the insertion of a central venous cannula (CVC) [2] [3]. Whilst the use of ultrasound-guided insertion will aid in the reduction of the incidence of such risks, many remain clinically significant (such as pneumothorax, arterial injury, arrhythmias and catheter- related infection) and so it seems sensible to consider circumstances wherein administration via PVC may be preferable when there is a need for: • stabilisation of critically unwell patients awaiting transfer to a critical care area; • short term post-operative use; • patient preference; • or where central venous access would prove problematic. The decision will ultimately come down to local policy and the responsible senior at the time.
  • 31. Monitoring Inotropes are usually only used in clinical areas where patients’ haemodynamics can be monitored adequately. Continuous monitoring of MAP, CO and CVP allows haemodynamic changes to be detected and addressed rapidly.
  • 32. Summary • Inotropic drugs are potentially dangerous so be very thorough in checking • Vascular access needs to be spot on • On central lines always endeavour to use distal, brown lumen(furthest) • Wear gloves when preparing/assisting • Know what the drug does and why we use it • Don’t EVER make a mistake with inotropes or disconnect them without direction
  • 33. Case 1 Type 1 anaphylactic reaction Type 1 anaphylactic reaction What will you need and why?…
  • 34. Case 2 Septic shock How would you approach this case ? Please explain why ?
  • 35. Case 3 Cardiac arrest (pre and post resuscitation)
  • 36. Case study 4 Cardiogenic shock Dobutamine Noradrenaline Management of cardiogenic shock article

Notas del editor

  1. M2 muscarinic receptors are located in the heart, where they act to slow the heart rate down to normal sinus rhythm after negative stimulatory actions of the parasympathetic nervous system, by slowing the speed of depolarization
  2. The circled area is where SYMP and PARA (&drugs) will have an effect on HR The sooner the drift line gets to TH – the sooner the HR
  3. Vasopressors are drugs that cause blood vessels to narrow, thereby increasing blood pressure and hence the flow of blood. They are used to treat patients with septic shock, helping to restore blood flow to the vital organs and the rest of the body. Think about preload and adequate fluid loading
  4.  SN located in the basal ganglia structure located in the midbrain that plays an important role in reward and movement
  5. Epinephrine- alpha-1-adrenergic agonist effects-increased vasoconstriction, peripheral resistance and decreased mucosal edema beta-1adrenergic agonist effects- increased inotropy and increased chronotropy beta-2-adrenergic agonist effects-increased bronchodilation, decreased release of mediators of inflammations from mast cells and basophils.
  6. Septic shock is when blood pressure drops to a dangerously low level after an infection. There is a high 02 demand to reduce cell death Noradrenaline- Causes vasoconstriction(alpha-adrenergic action) and positive inotropic effect of the heart and dilation of coronary arteries(beta-adrenergic action) Compared to dopamine, noradrenaline reduced deaths from any cause at 28 days by 11% (Relative Risk [RR] 0.89, 95% Confidence Interval [CI] 0.81 to 0.98). Forty-five percent of people treated with noradrenaline died, compared with 52% treated with dopamine. This result came from a meta-analysis of 11 trials. Noradrenaline reduced the risk of major adverse effects, such as irregular heart-beat, heart attack, stroke or reduction in blood supply (ischaemia) to the heart or limbs, by about two-thirds compared with dopamine (RR 0.34, 95% CI 0.14 to 0.84). This result came from a meta-analysis of just three trials. Meta-analysis of four trials found that noradrenaline reduced the risk of irregular heart beat by about a half compared to dopamine (RR 0.48, 95% CI 0.40 to 0.58). No reduction in all-cause mortality or major adverse effects was demonstrated for noradrenaline compared to adrenaline, phenylephrine, vasopressin or terlipressin as any difference in mortality were not statistically significant. Other outcomes, including length of stay in intensive care, were similar between the different vasopressors. However, noradrenaline did improve some other measures indicating stability of blood pressure and circulation, such as urine output.
  7. Give adrenaline 1 mg IV (IO) as soon as possible for adult patients in cardiac arrest with a non-shockable rhythm. Give adrenaline 1 mg IV (IO) after the 3rd shock for adult patients in cardiac arrest with a shockable rhythm. Repeat adrenaline 1 mg IV (IO) every 3-5 minutes whilst ALS continues. May consider vasopressin for treatment of asystole, but there is insufficient evidence to recommend for or against its use in PEA. Further studies are required. Epinephrine may be administered every 3 to 5 minutes during the attempted resuscitation; vasopressin may be substituted for the first or second epinephrine dose.
  8. Dobutamine may be given simultaneously to norepinephrine in an attempt to improve cardiac contractility which is often performed in clinical practice.7 Other inotropes such as levosimendan or phosphodiesterase-inhibitors are of interest in CS based on their improvement of myocardial contractility without increasing oxygen requirements and potential for vasodilation. However, as shown in a recent Cochrane review, the current evidence for inotropes and vasodilators in CS is very limited.